BOLT

Bolt Biotherapeutics, Inc. (BOLT) Risks & Opportunities Analysis (2026)

Invetso Score: 6.6/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 5.6 (Moderate)

Negative net debt and current ratio above 2.6 suggest limited balance-sheet stress, but zero interest coverage leaves BOLT more exposed than cash-generative peers if financing conditions tighten.

The extreme cash-conversion-cycle reading implies working-capital distortions can dominate reported liquidity, increasing outcome volatility versus peers with steadier receivables and payables dynamics.

Debt-to-equity above 1.7 indicates meaningful leverage relative to cleaner-capitalized peers, which can constrain flexibility if demand softens or refinancing windows narrow.

Missing FCF margin data limits visibility on cash durability, so BOLT appears less transparent than peers with consistent free-cash-flow disclosure and conversion history.

Opportunities

Score:

Net debt below zero and a current ratio above 2.6 provide stronger liquidity than many leveraged peers, supporting resilience if operating conditions remain uneven.

The very high payables-supported cash-conversion profile can preserve near-term cash, giving BOLT more working-capital flexibility than peers with longer cash cycles.

If leverage is being offset by operating cash generation, BOLT could compare favorably with peers that must prioritize debt service over growth investment.

Strong short-term liquidity metrics create room to absorb cyclical demand swings better than peers with tighter balance sheets, improving relative positioning over 1–5 years.

Overall Score

Score:

BOLT’s strong liquidity and net cash position support resilience versus peers, but leverage, zero interest coverage, and opaque cash-generation quality keep forward positioning only moderately attractive.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Bolt Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →